When the coronavirus pandemic began, the challenge for Pfizer and BioNTech wasn’t just developing a Covid-19 vaccine — they also had to make it, and by the hundreds of millions.When the coronavirus pandemic began, the challenge for Pfizer and BioNTech wasn’t just developing a Covid-19 vaccine — they also had to make it, and by the hundreds of millions.